Title: Design, synthesis and antimycobacterial activity of novel nitrobenzamide derivatives

Authors: Hongjian Wang, Kai Lv, Xiaoning Li, Bo Wang, Apeng Wang, Zeyu Tao, Yunhe Geng, Bin Wang, Menghao Huang, Mingliang Liu, Huiyuan Guo, Yu Lu

PII: S1001-8417(18)30331-0
DOI: https://doi.org/10.1016/j.cclet.2018.08.005
Reference: CCLET 4626

To appear in: *Chinese Chemical Letters*

Received date: 9-7-2018
Revised date: 9-8-2018
Accepted date: 10-8-2018

Please cite this article as: Wang H, Lv K, Li X, Wang B, Wang A, Tao Z, Geng Y, Wang B, Huang M, Liu M, Guo H, Lu Y, Design, synthesis and antimycobacterial activity of novel nitrobenzamide derivatives, *Chinese Chemical Letters* (2018), https://doi.org/10.1016/j.cclet.2018.08.005

Communication

Design, synthesis and antimycobacterial activity of novel nitrobenzamide derivatives

Hongjian Wang[a,1], Kai Lv[a,1], Xiaoning Li[a], Bo Wang[a], Apeng Wang[a], Zeyu Tao[a], Yunhe Geng[a], Bin Wang[b], Menghao Huang[c], Mingliang Liu[a,*], Huiyuan Guo[a], Yu Lu[b,*]

[a]*Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China*
[b]*Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China*
[c]*Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis 46202, United States*

Graphical abstract



We report herein the design and synthesis of a series of novel nitrobenzamide derivatives. Results reveal that **A6**, **A11**, **C1** and **C4** have not only the same excellent MIC values of <0.016 μg/mL against drug-resistant clinical isolates as lead **1**, but also acceptable safety indices (SI>1500), opening a new direction for further development.

ARTICLE INFO

Article history:
Received
Received in revised form
Accepted
Available online

Keywords: nitrobenzamides
synthesis
antimycobacterial activity
tuberculosis

ABSTRACT

We report herein the design and synthesis of a series of novel nitrobenzamide derivatives. Results reveal that many of them display considerable *in vitro* antitubercular activity. Four *N*-benzyl or *N*-(pyridine-2-yl)methyl 3,5-dinitrobenzamides **A6**, **A11**, **C1** and **C4** have not only the same excellent MIC values of <0.016 μg/mL against both drug-sensitive MTB strain H37Rv and two drug-resistant clinical isolates as PBTZ169 and the lead **1**, but also acceptable safety indices (SI>1500), opening a new direction for further development.

Tuberculosis (TB) has existed for millennia and remains a major global health problem [1]. It is a widespread infectious disease predominantly caused by *Mycobacterium tuberculosis* (MTB), which can be transmitted through the air as droplets and affects the lungs [2]. The World Health Organization (WHO) estimated that approximately 10.4 million people were infected and 1.3 million died from TB worldwide in 2016 [1]. The spread of multidrug-resistant TB (MDR-TB) and the emergence of extensively drug-resistant TB (XDR-TB) have reinvigorated drug discovery efforts in search of novel agents [3-6]. Despite the introduction of Bedaquiline [7] and Delamanid [8] to the repertoire of anti-TB therapies for MDR-TB, some adverse events have been noted [9]. Therefore, it is urgently needed to develop antimycobacterial molecules with new mechanisms of action and that are active against MDR- and XDR-TB [10].

Decaprenyl phosphoryl-*β*-D-ribose 2′-epimerase (DprE1) was identified as a potential target for developing potent and safer anti-TB agents [11-13]. Some new chemical entities (NCEs) were found to have potent activity against MDR/XDR-MTB as covalent or noncovalent inhibitors of the DprE1 enzyme [14-22], such as nitroaromatic compounds DNB1, MTX and PBTZ 169 (Fig. S1 in Supporting information). As the most advanced scaffold among

* Coerresponding authors.
E-mail addresss: lmllyx@126.com (M. Liu), luyu4876@hotmail.com (Y. Lu).

[1] These authors contributed equally to this work.

these NCEs, nitrobenzothiazinones (BTZs) have garnered great interest recently, and many series of BTZ derivatives were reported [23-26]. Above all, candidate PBTZ169 entered in Phase II clinical trials in 2017 [1].

In our previous studies, many BTZs containing various cyclic ketoximes, spiro-heterocycles and piperidines moieties were found to have considerable antitubercular activity [27-29]. Recently, *N*-(4-(4-trifluoromethyl)piperidin-1-yl)benzyl nitrobenzamides **1** and **2** (Fig. 1) were identified as new anti-TB agents by the thiazinone ring opening of PBTZ169 in our lab [30]. Both of them with simpler structures than PBTZ169, show potent activity against MTB H37Rv strain (MIC ≤ 0.016 μg/mL). Moreover, compound **1** also displays acceptable safety and better PK properties than PBTZ169.

Inspired by the above research results, compounds **1** and **2** were employed as lead compounds, and the three moieties (A, B and C ring) were all explored in this study. We started with the modification of A ring and B ring. Replacement of X group on ring A with various substituents (Y) leaded to 3-nitrobenzamides bearing *N*-benzyl (**A1-4**); introduction of pyridine as A ring while reserving the nitro group gave 5-nitronicotinamides **A5**. Subsequently, the B ring was changed to pyrin-3-yl or pyrin-2-yl leading to compounds **B1-5** or **C1-3** (Fig. 1). After identifying the optimal A and B rings, C ring was then further investigated. Our primary objective was to find optimized benzamides with potent antimycobacterial activity. A preliminary structure-activity relationship (SAR) study was also explored to facilitate the further development of these compounds.

Detailed synthetic pathways to side chains **6–8**, leads **1**, **2** and targets **A–C** are shown in Schemes S1 and S2 (Supporting information), respectively. Commercially unavailable benzylamines and pyridinylmethylamines **6–8** were first prepared according to Scheme S1. 4-Fluorobenzonitrile **3**, 6-fluoronicotinonitrile **4** and 5-fluoropicolinonitrile **5** were treated with various nitrogen heterocyclic amines ZH in DMSO in the presence of K_2CO_3 at 80 °C, and the resulting condensates were subsequently reduced with $LiAlH_4$ in THF to produce the desired compounds **6**, **7** and **8**, respectively.

Leads **1**, **2** and targets **A1-11, B1-21**, **C1-4** were easily obtained by coupling 3-nitrobenzoic acids **9–13** and 5-nitronicotinic acid **14** with the above side chain compounds **6–8** or commercially available benzylamines **15a–d** in the presence of triethylamine and condensation agent bis(2-oxo-3-oxazolidinyl) phosphonic chloride (BOP-Cl) (Scheme S2).

Table 1

Structures and activity of compounds **A–C** against MTB H37Rv.



A1-4



B1-4 (pyrin-3-yl) **C1, C2** (pydin-2-yl)

Compd.	Y	MIC (μg/mL)	Compd.	Y	MIC (μg/mL)
1	5-NO_2	<0.016	**B3**	4,6-di-Cl	>16
2	5-CF_3	0.016	**B4**	H	15.354
A1	5-F	1.357	**B5**		15.176
A2	5-Br	0.459	**C1**	5-NO_2	<0.016
A3	4,6-di-Cl	>16	**C2**	H	31.088
A4	H	>16	**C3**		15.732
A5		14.735	PBTZ169		<0.016
B1	5-NO_2	0.059	INH		0.0781
B2	5-Br	0.944	RFP		0.0781

INH: isoniazid; RFP: rifampicin.

The target compounds **A1–5**, **B1–5** and **C1–3** bearing different kinds of substituents to ensure A and B rings flexibility and structure diversity, were first synthesized. They were preliminarily screened for *in vitro* activity against MTB H37Rv ATCC27294 strain, using the Microplate Alamar Blue Assay (MABA) [31,32]. The minimum inhibitory concentration (MIC) is defined as the lowest concentration effecting a reduction in fluorescence of >90%

relative to the mean of replicate bacterium-only controls. The MIC values of the compounds along with the leads **1** and **2**, PBTZ169, isoniazid (INH), and rifampicin (RFP) for comparison were obtained from three independent experiments and presented in μg/mL in Table 1.

Effect of the substituents on A ring was first investigated. The nature and position of the substituents greatly influence activity. Replacement of one nitro group of **1** or the trifluoromethyl of **2** with halogen in compounds **A1**（F） and **A2** (Br) leads to decreased activity (MIC: 1.357 and 0.459 μg/mL, respectively). Introduction of 4,6-dichloro (**A3**) or reservation of one nitro (**A4**) destroys activity. Moreover, *N*-benzyl nicotinamide analogue (**A5**) displays very poor potency. Overall, these results reveal that the presence of a strong electron-withdrawing group (CF_3, NO_2) at C-5 position of nitrobenzamide core is essential for excellent activity (Table 1).

Table 2

Structures and activity of 3,5-dinitrobenzamides **A–C** against MTB H37Rv.



A6-11



B6-21 (pyrin-3-yl) **C4** (pydin-2-yl)

Compd.	Z	MIC (μg/mL)	Compd.	Z	MIC (μg/mL)
A6		<0.016	**B12**		0.452
A7		0.060	**B13**		0.235
A8	F	0.120	**B14**		0.480
A9	CF_3	0.059	**B15**		1.255
A10	OCF_3	0.033	**B16**		0.210
A11	OCH_3	<0.016	**B17**		0.178
B6		0.094	**B18**		0.233
B7		0.030	**B19**		0.491
B8		0.030	**B20**		0.973
B9		0.108	**B21**		0.143
B10		0.059	**C4**		<0.016
B11		0.119	PBTZ169		<0.016

In further modifications, the benzene ring (B ring) was replaced by a pyridine ring. As shown in Table 1, in accordance with SAR of *N*-benzyl analogues (**A1**–**5**), *N*-(pyridin-3-yl)methyl and *N*-(pyridin-2-yl)methyl 3,5-dinitrobenzamides (**B1**, **C1**) demonstrate potent MIC values of 0.059 and <0.016 μg/mL against this strain, respectively, indicating that *N*-pyridinylmethyl on the amide is also acceptable.

Based on the above SAR, and better activity of lead compound **1** than **2**, *N*-benzyl and *N*-pyridinylmethyl 3,5-dinitrobenzamides with various groups at *para*-position of B ring were further designed and synthesized. As shown in Table 2, all of them show good to excellent activity against MTB H37Rv strain (MIC: <0.016–0.973 μg/mL), with

one exception **B15**. Among them, nine compounds **A6, 7, 9**–**11**, **B7, 8, 10** and **C4** (MIC: <0.016–0.060 μg/mL) are more active than INH/RFP (MIC: 0.0781 μg/mL), and roughly comparable to PBTZ169.

[a]MDR-TB 16833 and MDR-TB 16995 were isolated from patients in Beijing Chest Hospital; [b]the 50% cytotoxic concentration; [c]SI: selectivity index for MTB H37Rv, CC_{50} / MIC

For *N*-benzyl 3,5-dinitrobenzamides, the presence of a halogen atom instead of trifluoromethyl at *para*-position of the piperidine ring (C ring) was found to be also favorable. For example, compound **A6** shows the same MIC value of <0.016 μg/mL as the lead **1**. Introduction of an additional aromatic moiety on C ring, such as 4-fluorophenyl (**A7**, MIC: 0.059 μg/mL), is also acceptable. More interestingly, removal of C ring and direct attachment of a simple group to B ring remain considerable activity (**A8**–**11**), and an electron-donating group (OCH_3) is preferred over an electron-withdrawing one (CF_3, OCF_3) or a halogen atom (F).

For *N*-(pyridin-3-yl)methyl 3,5-dinitrobenzamides, the presence of a halogen atom (Cl, Br) instead of trifluoromethyl on C ring is more beneficial to activity (**B1** *vs.* **B7** and **B8**), and replacement of C ring in **B1** with thiomorpholine in compound **B10** maintains the same potent activity (MIC: 0.059 μg/mL). However, introduction of 4-substituented phenyls on C ring, or replacement of the piperidine with piperazines bearing a substituted phenyl moiety leads decreased activity (**B1** *vs* **B11**–**21**). Conversely, *N*-(pyridin-2-yl)methyl compound **C4** with a 4-(fluorophenyl)piperazine as C ring, displays the same potent MIC value of <0.016 μg/mL as **C1**, much more active than the corresponding *N*-(pyridin-3-yl)methyl analogue **B16** (MIC: 0.210 μg/mL) (Table 2).

Encouraged by their strong potency against the drug sensitive MTB H37Rv strain (MIC: <0.016–0.060 μg/mL), eleven 3,5-dinitrobenzamide derivatives **A6**, **7**, **9**–**11**, **B1**, **7**, **8**, **10** and **C1**, **4** were further evaluated against two clinical isolated MTB-MDR (16833 and 16995) strains resistant to both INH and RFP. The cytotoxic potential of these compounds was also investigated in a mammalian Vero cell line by MTS assay. As shown in Table 3, all of them exhibit potent MIC values of <0.016–0.071 μg/mL, similar to that against MTB H37Rv. Among of them, compounds **A6**, **A11, C1** and **C4** have the same excellent activity (MIC: <0.016 μg/mL) as PBTZ169 and the lead **1**. With a few exceptions, these compounds (CC_{50}: 22.63–34.57 μg/mL) are less cytotoxic than the lead **1**, although generally more cytotoxic than PBTZ169.

Lipinski's rules are important guidelines for determining drug-likeness compounds [33]. The related values of most potent compounds **A6**, **A11**, **C1** and **C4** were calculated using the online chemo-informatics software molinspiration (http://www.molinspiration.com). As shown in Table S1 (Supporting information), none violation of Lipinski's rule-of-five was found among compounds **A6**, **A11**, and **C1**. The hydrogen bond acceptors of compound **C4** (HBA = 11) are more than the recommended number (HBA <10). However, compound **C4** is still incorporate with the Lipinski's rule-of-five (violations ≤1). Thus, these compounds display good drug like properties, are all deserved further development.

In conclusion, a series of nitrobenzamide derivatives containing *N*-benzyl or *N*-pyridinylmethyl moieties, based on lead compounds **1** and **2** discovered in our lab, were designed and synthesized as new anti-TB agents. Many of them exhibit potent *in vitro* antitubercular activity. Especially, *N*-benzyl 3,5-dinitrobenzamides **A6** and **A11**, and *N*-(pyridine-2-yl)methyl analogues **C1** and **C4** have not only the same excellent activity (MIC: <0.016 μg/mL) against both drug-sensitive MTB strain H37Rv and two drug-resistant clinical isolates as PBTZ169 and the lead **1**, but also have acceptable safety indices (SI: >1500). In addition, compounds **A6**, **A11**, **C1** and **C4** display good drug like properties, suggesting these compounds may serve as new and promising candidates for further antitubercular drug discovery. By the way, the further expansion of the 3,5-dinitrobenzamides is underway to find potent anti-TB agents.

Acknowledgments

This work is supported by the National Mega-project for Innovative Drugs (Nos. 2015ZX09102007-008, 2015ZX09102007-015, 2015ZX09304006-016, 2018ZX09721001-004-007, 2018ZX09711001-007-002), CAMS Initiative for Innovative Medicine (No. 2016-I2M-1-010), CAMS Innovation Fund for Medical Science (Nos. CAMS-2016-I2M-1-010, CAMS-2017-I2M-1-011), PUMC Youth Fund (No. 2017350011).

References

[1] Global Tuberculosis Report 2017, World Health Organization, www.who.Int/tb/publications/lpa-mdr-diagnostics/en/.

[2] N. Nayak, J. Ramprasad, U. Dalimba, et al., Chin. Chem. Lett. 27 (2016) 365-369.
[3] A. Wang, Y. Yang, J. Yang, et al., Bioorg. Med. Chem. 26 (2018) 2073-2084.
[4] Z. Xu, S. Zhang, C. Gao, et al., Chin. Chem. Lett. 28 (2017) 159-167.
[5] K. Lv, L. Li, B. Wang, et al., Eur. J. Med. Chem. 137 (2017) 117-125.
[6] R.S. Wallis, M. Maeurer, P. Mwaba, et al., Lancet Infect Dis.16 (2016) 34-46.
[7] A.K. Kakkar, N. Dahiya, Tuberculosis (Edinb) 94 (2014) 357-362.
[8] M.T. Gler, V. Skripconoka, E. Sanchez-Garavito, et al., N. Engl. J. Med. 366 (2012) 2151-2160.
[9] D.T. Hoagland, J. Liu, R.B. Lee, R.E. Lee, Adv. Drug Deliv. Rev. 102 (2016) 55-72.
[10] Beena, D.S. Rawat, Med. Res. Rev. 33 (2013) 693-764.
[11] G. Manina, M.R. Pasca, S. Buroni, E. de Rossi, G. Riccardi, Curr. Med. Chem. 17 (2010) 3099-3108.
[12] G. Riccardi, M.R. Pasca, L.R. Chiarelli, et al., Appl. Microbiol. Biotechnol. 97 (2013) 8841-8848.
[13] M. Brecik, I. Centarova, R. Mukherjee, et al., ACS Chem. Biol. 10 (2015) 1631-1636.
[14] P.K. Crellin, R. Brammananth, R.L. Coppel, PloS One 6 (2011) e16869.
[15] S.A. Stanley, S.S. Grant, T. Kawate, et al., ACS Chem. Biol. 7 (2012) 1377-1384.
[16] F. Wang, D. Sambandan, R. Halder, et al., Proc. Natl. Acad. Sci. U. S. A. 110 (2013) 2510-2517.
[17] M. Naik, V. Humnabadkar, S.J. Tantry, et al., J. Med. Chem. 57 (2014) 5419-5434.
[18] M. Panda, S. Ramachandran, V. Ramachandran, et al., J. Med. Chem. 57 (2014) 4761-4771.
[19] P.S. Shirude, R. Shandil, C. Sadler, et al., J. Med. Chem. 56 (2013) 9701-9708.
[20] T. Christophe, M. Jackson, H.K. Jeon, et al., PLoS Pathog. 5 (2009) e100645.
[21] K.J. Schaper, M. Pickert, A.W. Frahm, Archiv der Pharmazie 332 (1999) 91-102.
[22] C. Trefzer, M. Rengifo-Gonzalez, M.J. Hinner, et al., J. Am. Chem. Soc. 132 (2010) 13663-13665.
[23] V. Makarov, G. Manina, K. Mikusova, et al., Science 324 (2009) 801-804.
[24] V. Makarov, B. Lechartier, M. Zhang, et al., EMBO Mol. Med. 6 (2014) 372-383.
[25] A.L.D.L. Ribeiro, G. Degiacomi, F. Ewann, et al., PloS One 6 (2011) e26675.
[26] T. Karoli, B. Becker, J. Zuegg, et al., J. Med. Chem. 55 (2012) 7940-7944.
[27] R. Zhang, K. Lv, B. Wang, et al., RSC Adv. 7 (2017) 1480-1483.
[28] K. Lv, X. You, B. Wang, et al., ACS Med. Chem. Lett. 8 (2017) 636-641
[29] K. Lv, Z. Tao, Q. Liu, et al., Eur. J. Med. Chem. 151 (2018) 1-8.
[30] L. Li, K. Lv, Y. Yang, et al., ACS Med. Chem. Lett. 9 (2018) 741-745.
[31] L. Collins, S.G. Franzblau, Antimicrob. Agents Chemother. 41 (1997) 1004-1009.
[32] Y. Lu, M. Zheng, B. Wang, et al., Antimicrob. Agents Chemother. 55 (2011) 5185-5193.
[33] C. A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney. Adv. Drug Deliv. Rev. 46 (2001) 3-26.



Fig. 1. Design of the new molecules.

Table 3

Activity against MDR-MTB, cytotoxicity and selectivity index (SI) values for selected compounds.

Compd.	MIC (μg/mL)		CC_{50}[b] (μg/mL)	SI[c]
	MDR-MTB 16833[a]	MDR-MTB 16995[a]		
1	<0.016	<0.016	20.15	>1259
A6	<0.016	<0.016	24.74	>1546
A7	0.071	0.056	10.51	175
A9	0.070	0.042	33.62	569
A10	0.029	0.056	31.21	945
A11	<0.016	<0.016	28.02	>1751
B1	0.043	0.028	16.80	284
B7	0.030	0.056	23.17	772
B8	0.030	0.029	22.63	754
B10	0.063	0.060	17.60	298
C1	<0.016	<0.016	26.61	>1663
C4	<0.016	<0.016	34.57	>2160
PBTZ169	<0.016	<0.016	36.68	>2292
INH	>40	>40	NT	
RFP	>40	>40	NT	